Investors & Media

New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy

Interim results from RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma ® (onasemnogene abeparvovec)  CARLSBAD, Calif. , June 30, 2023 /PRNewswire/ — Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data

Read more
You are now leaving to visit